| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2021cafa8df7b0dec20ae2c7682f639 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4427 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2020-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17968daf92afdfec163f6bcef2fadbbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fee271f87ef8a959683aa4c538bd03ae |
| publicationDate |
2022-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022288063-A1 |
| titleOfInvention |
Targeting wnk1 in blood cancers |
| abstract |
The present invention relates to lysine deficient protein kinase 1 (WNK1) inhibitors for use in treating patients with blood cancers, in particular leukemia and multiple myeloma. |
| priorityDate |
2019-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |